Chemours (NYSE:CC) Stock Rating Raised to “Hold” at Barclays

Barclays upgraded shares of Chemours (NYSE:CC) to a hold rating in a research note published on Monday morning,Zacks reports.

A number of other research analysts also recently weighed in on the company. Zacks Research upgraded Chemours from a “strong sell” rating to a “hold” rating in a report on Thursday, September 10th. BMO Capital Markets reduced their price objective on Chemours from $26.00 to $18.00 and set an “outperform” rating for the company in a research note on Thursday, August 13th. Weiss Ratings downgraded Chemours from a “sell (d)” rating to a “sell (d-)” rating in a research note on Thursday, August 6th. JPMorgan Chase & Co. decreased their price objective on Chemours from $22.00 to $15.00 and set a “neutral” rating for the company in a research report on Thursday, August 13th. Finally, The Goldman Sachs Group reaffirmed a “neutral” rating and set a $16.00 target price on shares of Chemours in a research note on Friday, October 9th. Three research analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $18.09.

Chemours Trading Down 2.9%

Shares of NYSE CC opened at $12.81 on Monday. Chemours has a 12 month low of $10.44 and a 12 month high of $28.67. The company has a market cap of $1.93 billion, a price-to-earnings ratio of -6.71 and a beta of 1.41. The company has a quick ratio of 0.88, a current ratio of 1.66 and a debt-to-equity ratio of 18.98. The business has a fifty day simple moving average of $14.79 and a 200-day simple moving average of $18.97.

Chemours (NYSE:CC) last posted its quarterly earnings data on Tuesday, August 4th. The specialty chemicals company reported $0.42 EPS for the quarter, missing analysts’ consensus estimates of $0.49 by ($0.07). Chemours had a negative net margin of 5.00% and a positive return on equity of 60.64%. The firm had revenue of $1.59 billion for the quarter, compared to analysts’ expectations of $1.65 billion. During the same period in the prior year, the company posted ($2.54) earnings per share. Chemours’s quarterly revenue was down 1.5% compared to the same quarter last year. Sell-side analysts predict that Chemours will post 0.84 EPS for the current year.

Chemours Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, September 15th. Investors of record on Friday, August 14th were paid a $0.0875 dividend. This represents a $0.35 dividend on an annualized basis and a dividend yield of 2.7%. The ex-dividend date of this dividend was Friday, August 14th. Chemours’s dividend payout ratio (DPR) is presently -18.32%.

Insider Buying and Selling

In other news, insider Calderon Gerardo Familiar purchased 1,935 shares of the company’s stock in a transaction dated Wednesday, August 12th. The shares were bought at an average price of $15.53 per share, with a total value of $30,050.55. Following the completion of the transaction, the insider directly owned 58,547 shares in the company, valued at $909,234.91. This trade represents a 3.42% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Shane Hostetter bought 3,350 shares of the stock in a transaction that occurred on Thursday, August 6th. The stock was purchased at an average price of $14.94 per share, for a total transaction of $50,049.00. Following the completion of the purchase, the chief financial officer directly owned 102,698 shares in the company, valued at $1,534,308.12. The trade was a 3.37% increase in their position. The disclosure for this purchase is available in the SEC filing. In the last ninety days, insiders purchased 8,663 shares of company stock worth $130,601. 0.85% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Chemours

Several hedge funds and other institutional investors have recently made changes to their positions in CC. The Manufacturers Life Insurance Company bought a new stake in shares of Chemours during the second quarter worth $1,522,000. Deutsche Bank AG acquired a new position in shares of Chemours during the second quarter worth $3,291,000. BlackRock Inc. bought a new position in shares of Chemours in the 2nd quarter valued at $477,769,000. Old West Investment Management LLC bought a new position in shares of Chemours in the 2nd quarter valued at $7,152,000. Finally, Jefferies Financial Group Inc. bought a new position in shares of Chemours in the 2nd quarter valued at $15,996,000. 76.26% of the stock is owned by institutional investors and hedge funds.

Chemours News Summary

Here are the key news stories impacting Chemours this week:

• Positive Sentiment: BMO Capital reaffirmed its Buy rating, indicating that some analysts still see recovery potential in Chemours despite the recent weakness. BMO Capital reaffirms Buy rating
• Neutral Sentiment: Barclays initiated coverage at Equal Weight, while Mizuho maintained a Neutral rating but reduced its price target to $15 from $18. The new target still implies potential upside from recent trading levels, but the cut signals more cautious expectations. Mizuho downgrades Chemours
• Negative Sentiment: RBC Capital downgraded Chemours to Sector Perform from Outperform and cut its price target to $14 from $22, citing persistent TiO₂ weakness, soft chemical demand and potential headwinds in the Thermal & Specialized Solutions segment through year-end. RBC downgrades Chemours
• Negative Sentiment: Several law firms announced or promoted a securities-fraud class action filed against Chemours and certain officers. The case covers investors who purchased shares from February 20 through August 4, 2026, and alleges investors were harmed by disclosures concerning Opteon refrigerant aftermarket demand. The lead-plaintiff deadline is December 7, 2026. Although the allegations have not been proven, the litigation creates legal, financial and reputational risks. Chemours securities-fraud class action

Chemours Company Profile

The Chemours Company (NYSE: CC) is a global chemical company that develops, manufactures and distributes specialty chemical products used in a range of industrial and consumer applications. Its portfolio serves markets including coatings, plastics, automotive, refrigeration and air conditioning, electronics, telecommunications, energy, healthcare and general manufacturing.

Chemours operates through three primary business segments: Titanium Technologies, Thermal & Specialized Solutions, and Advanced Performance Materials.